Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Ranibizumab (Lucentis) Monotherapy Versus Combination of Ranibizumab (Lucentis) With Photodynamic Therapy (Verteporfin) in Patients With Subfoveal Choroidal Neovascularisation Due to Age-Related Macular Degeneration - a Pilot Study

NCT01570608 is registered in ClinicalTrials.gov with The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery as lead sponsor.

NCT NCT01570608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01570608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Ranibizumab (Lucentis) Monotherapy Versus Combination of Ranibizumab (Lucentis) With Photodynamic Therapy (Verteporfin) in Patients With Subfoveal Choroidal Neovascularisation Due to Age-Related Macular Degeneration - a Pilot Study
Lead sponsor
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2007
Completion date
August 31, 2011
Enrollment
51 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration